Given these observations, we believe that SYPL-1 could offer complementary clinical value alongside existing biomarkers and may provide insights into alternative molecular processes in pancreatic cancer, warranting further mechanistic investigations. Here, SYPL1 is linked to pancreatic neoplasm.